Skin Cancer – Cancer Trials Ireland

Cancer Trials Ireland > Cancer Trials > Skin Cancer

MK-3475-630/KEYNOTE-630

Name	No.	For Patients with	Purpose
MK-3475-630/KEYNOTE-630	CTRIAL-IE 20-08	Melanoma	This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).

R3767-ONC-1613

Name	No.	For Patients with	Purpose
R3767-ONC-1613	CTRIAL-IE 20-11	Melanoma	This study is to evaluate preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab as measured by objective response rate (ORR).

BMS CA045-001

Name	No.	For Patients with	Purpose
BMS CA045-001	CTRIAL-IE 18-51	Melanoma.	This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab

BMS CA209-8FC

Name	No.	For Patients with	Purpose
BMS CA209-8FC	CTRIAL-IE 19-13	Melanoma.	The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C

CA045-001

Name	No.	For Patients with	Purpose
CA045-001	18-51	Previously untreated or unresectable or Metastatic Melanoma	The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.

R2810-ONC-1788

Name	No.	For Patients with	Purpose
R2810-ONC-1788	18-50	Cutaneous Squamous Cell Carcinoma (High Risk)	The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).